cagrisema combination cagrilintide semaglutide phase 3 results 2025 HCPLive ADA 2025: CagriSema Demonstrates Dual

Sports Health

*Disclaimer: Peptides are not FDA-approved for veterinary use and should only be used under veterinary supervision

These titration figures mirror published schedules for the branded CagriSema pharmaceutical and are not approved human dosing for this compounded research blend

The blend is well tolerated, with gastrointestinal effects being the most frequent adverse events and no evidence of clinically significant safety concerns or neutralizing antibody responses to cagrilintide during short-term exposure 1-3

Scores on the Three-Factor Eating Questionnaire (TFEQ-R18) improved in all treatment groups, with Cagrilintide producing greater improvements than placebo in specific domains: cognitive restraint, notably at 1.2 mg and 4.5 mg, emotional eating notably at 0.3 mg and 2.4 mg, and uncontrolled eating notably at 1.24.5 mg